Pneumococcal Infections Pipeline: 15+ Pioneering Companies Shaping the Next Generation of Advanced Treatments | DelveInsight

The pneumococcal infection market is witnessing a surge in vaccine innovation, fueled by leaders such as CanSino Biologics, Pfizer, Merck Sharp & Dohme, EuBiologics, Beijing Zhifei Lvzhu Biopharmaceutical, SK Chemicals, and LG Life Sciences. With next-gen conjugate vaccines targeting broader serotype coverage, these companies are stepping up preventive strategies to combat evolving bacterial threats in both pediatric and elderly populations.

DelveInsight's "Pneumococcal Infections Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the pneumococcal infections market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Pneumococcal infections drugs, the pneumococcal infections pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Pneumococcal Infections Pipeline Report
• DelveInsight's pneumococcal infections pipeline analysis depicts a robust space with 15+ active players working to develop 20+ pipeline drugs for pneumococcal infections treatment.
• The leading pneumococcal infections companies include GlaxoSmithKline, Gangagen, CanSino Biologics Inc., Pfizer, Merck Sharp & Dohme, EuBiologics, Beijing Zhifei Lvzhu Biopharmaceutical, SK Chemicals Co., Ltd., LG Life Sciences, Astellas Pharma, Affinivax, ImmunoBiology, Panacea Biotech, SutroVax, Vaxcyte, and others are evaluating their lead assets to improve the pneumococcal infections treatment landscape.
• Key pneumococcal infections pipeline therapies in various stages of development include Research programme: Pneumococcal infections therapeutics, Pneumococcal vaccine, PF 06842433, V 116, EuPCV15, V 114, ASP3772, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine, Pneumococcal vaccine conjugate 10-valent, VAX 24, VAX XP, and others.
• In June 2024, the FDA approved CAPVAXIVETM (V116), a 21-valent pneumococcal conjugate vaccine, for preventing invasive pneumococcal disease and pneumonia in adults, targeting serotypes linked to about 84% of cases in those aged 50 and above.
• In April 2023, the FDA approved Pfizer's PREVNAR 20® for preventing invasive pneumococcal disease in children aged six weeks to 17 years, and otitis media in infants, covering 20 pneumococcal serotypes.

Request a sample and discover the recent breakthroughs happening in the pneumococcal infections pipeline landscape @ https://www.delveinsight.com/report-store/pneumococcal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pneumococcal Infections Overview
Pneumococcal infections are caused by Streptococcus pneumoniae, a gram-positive, catalase-negative bacterium commonly known as pneumococcus. The bacteria spread through direct contact with infected individuals or by healthy carriers who harbor the bacteria in their nasal passages. These infections can range from mild to severe, with symptoms varying depending on the infection site. The most common pneumococcal infections affect the lungs (pneumonia), middle ear (otitis media, especially in children), and sinuses (sinusitis).

Pneumococcal infections are categorized into two types: non-invasive, which occur outside major organs or the bloodstream and are typically less severe, and invasive, which affect major organs or the bloodstream and are generally more serious. Individuals with weakened immune systems are particularly vulnerable to these infections. Diagnosis is made based on a physical exam and medical history, while treatment involves antibiotics and vaccines for prevention.

Find out more about pneumococcal infections medication @ https://www.delveinsight.com/report-store/pneumococcal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pneumococcal Infections Treatment Analysis: Drug Profile
ASP3772: Affinivax
ASP3772 is a next-generation pneumococcal vaccine candidate developed to stimulate both B-cell (antibody-mediated) and T-cell immune responses against Streptococcus pneumoniae. It incorporates 24 pneumococcal polysaccharides along with two conserved pneumococcal proteins. Phase II clinical trials showed that ASP3772 was well tolerated and generated strong antibody responses to all included polysaccharides and proteins. The U.S. FDA granted Breakthrough Therapy designation for ASP3772 for preventing pneumonia and invasive disease in adults aged 50 and above, based on encouraging Phase II data. This designation aims to accelerate the development of promising treatments for serious or life-threatening conditions.

VAXNEUVANCE: Merck (MSD K.K.)
VAXNEUVANCE is a 15-valent pneumococcal conjugate vaccine from MSD K.K. (Merck Sharp & Dohme LLC), approved for use in individuals six weeks and older to prevent invasive disease caused by specific Streptococcus pneumoniae serotypes. Administered via intramuscular injection, it's contraindicated in individuals with severe allergic reactions to vaccine components or diphtheria toxoid. Approved by Japan's PMDA in 2023, VAXNEUVANCE demonstrated strong immunogenicity in local Phase II and III studies-showing non-inferior responses to PCV13 for shared serotypes and superior efficacy for serotypes 3, 22F, and 33F. The U.S. FDA initially approved it in July 2021 for adults, followed by pediatric approval in 2022.

Key Pneumococcal Infections Therapies and Companies
• ASP3772: Affinivax
• PREVENAR 20: Pfizer
• VAXNEUVANCE: MSD K.K

Learn more about the novel and emerging pneumococcal infections pipeline therapies @ https://www.delveinsight.com/report-store/pneumococcal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pneumococcal Infections Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

By Molecule Type
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Scope of the Pneumococcal Infections Pipeline Report
• Coverage: Global
• Key Pneumococcal Infections Companies: GlaxoSmithKline, Gangagen, CanSino Biologics Inc., Pfizer, Merck Sharp & Dohme, EuBiologics, Beijing Zhifei Lvzhu Biopharmaceutical, SK Chemicals Co., Ltd., LG Life Sciences, Astellas Pharma, Affinivax, ImmunoBiology, Panacea Biotech, SutroVax, Vaxcyte, and others.
• Key Pneumococcal Infections Pipeline Therapies: Research programme: Pneumococcal infections therapeutics, Pneumococcal vaccine, PF 06842433, V 116, EuPCV15, V 114, ASP3772, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine, Pneumococcal vaccine conjugate 10-valent, VAX 24, VAX XP, and others.

Dive deep into rich insights for drugs used for pneumococcal infections treatment; visit @ https://www.delveinsight.com/report-store/pneumococcal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Pneumococcal Infections Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Pneumococcal Infections Pipeline Therapeutics
6. Pneumococcal Infections Pipeline: Late-Stage Products (Phase III)
7. Pneumococcal Infections Pipeline: Mid-Stage Products (Phase II)
8. Pneumococcal Infections Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. Through our subscription-based platform, PharmDelve, you can get hassle-free access to all the healthcare and pharmaceutical market research reports.

This release was published on openPR.